Sign in

Private company

Ambrx Biopharma Cayman, Inc.

Biological products company in the Cayman Islands1

In its 2023 annual report the company says: “We are a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics, or EPBs, using our proprietary expanded genetic code technology platform that allows us to incorporate, in a site-specific manner, synthetic amino acids, or SAAs, into proteins within living cells.”43 It is headquartered in La Jolla, California.1

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersLa Jolla, California1
  • Incorporated inCayman Islands2
  • Business address10975 North Torrey Pines Road, La Jolla, Ca 920372
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-1032.2%Operating margin3
-1053.7%Net margin3
-0.7%Revenue growth, 20223
-66.2%Return on equity3
-$69.7MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development95¢$53.3M
  • Interest2¢$968.0K
  • Income tax3¢$1.9M

Out of $7.4M in revenue.3 The company lost money this year.

Financial statements

Revenue43$7.4M in 2022−28% since 2019
0$5.0M$10.0M$15.0M2019: $10.3M$10.3M20192020: $13.7M$13.7M2020+33%2021: $7.5M$7.5M2021−45%2022: $7.4M$7.4M2022−1%
Operating income43-$76.4M in 2022+240% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$22.5M-$22.5M20192020: -$13.1M-$13.1M2020−42%2021: -$64.4M-$64.4M2021+391%2022: -$76.4M-$76.4M2022+19%
Net income43-$78.0M in 2022+289% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$20.1M-$20.1M20192020: -$16.5M-$16.5M2020−18%2021: -$68.1M-$68.1M2021+312%2022: -$78.0M-$78.0M2022+15%
Fiscal year20182019202020212022
Revenue$10.3M4$13.7M4$7.5M3$7.4M3
Research and development$26.4M4$20.4M4$54.3M3$53.3M3
Operating expenses$71.9M3$83.8M3
Operating income-$22.5M4-$13.1M4-$64.4M3-$76.4M3
Interest$03$968.0K3
Income before tax-$68.3M3-$76.1M3
Income tax-$2.0K4$1.0K4$1.0K3$1.9M3
Net income-$20.1M4-$16.5M4-$68.1M3-$78.0M3
Earnings per share-$0.483-$0.293
Earnings per share (diluted)-$0.483-$0.293
Shares (weighted, basic)143.2M shares3270.2M shares3
Shares (weighted, diluted)143.2M shares3270.2M shares3

Compare Ambrx Biopharma Cayman, Inc. with another company

Corporate structure

Ambrx Biopharma Cayman, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Ambrx Biopharma Cayman, Inc.

  • Ambrx Biopharma Cayman, Inc. La Jolla, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Ambrx Biopharma Cayman, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$8.7M3 Dec 31, 2022$7.8M3 Dec 31, 2021+10.3%
Accumulated depreciation$5.6M3 Dec 31, 2022$4.9M3 Dec 31, 2021+15.4%
Property and equipment, net$3.0M3 Dec 31, 2022$3.0M3 Dec 31, 2021+2.0%
Operating-lease assets (leased space)$11.0M3 Dec 31, 2022$12.7M3 Dec 31, 2021−13.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$55.6M3 Dec 31, 2022$170.1M3 Dec 31, 2021−67.3%
Marketable securities, current$28.9M3 Dec 31, 2022$03 Dec 31, 2021
Marketable securities, non-current$16.8M3 Dec 31, 2022$03 Dec 31, 2021
Debt securities available for sale$45.7M3 Dec 31, 2022

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$25.2M3 Dec 31, 2022$36.0M3 Dec 31, 2021−29.8%
Accumulated amortization-$10.4M3 Dec 31, 2022-$9.6M3 Dec 31, 2021−8.1%
Finite-lived intangibles, net$4.3M3 Dec 31, 2022$15.0M4 Dec 31, 2021−71.3%

Leadership

Who has led Ambrx Biopharma Cayman, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Sonja Nelson2023

Chief operating officer

  1. Andrew Aromando2023
2025
Board members and other officers (9)

Former names

  • Ambrx Biopharma Inc.Feb 3, 2021 to Oct 10, 20232

Timeline

  1. Oct 12, 20238-K Listing notice or transfer; Change to shareholders' rights; Executive or director change18
  2. Oct 10, 20238-K Shareholder vote; Other events19
  3. Oct 6, 20238-K Executive or director change20
  4. Sep 25, 20238-K Ended a material agreement; Other events21
  5. Sep 15, 20238-K Entered a material agreement; Other events22
  6. Sep 6, 20238-K Executive or director change23
  7. Aug 25, 20238-K Other events24
  8. Jun 28, 20238-K Results of operations; Other events25
  9. Jun 8, 20238-K Shareholder vote26
  10. May 25, 20238-K Entered a material agreement; Other events27
  11. May 18, 20238-K Executive or director change28
  12. May 16, 20238-K Executive or director change29

Calendar

When it reported results

  1. Jun 28, 2023Reported quarterly or annual results25
  2. Feb 6, 2023Reported quarterly or annual results30

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

136 filings to the SEC since October 2021: 2 annual reports, 2 quarterly reports, 21 major events, 40 insider forms, 25 large holders, 46 other. The latest 20:

  1. Feb 9, 2024SC 13G/A EDGAR
  2. Oct 23, 202315-12G EDGAR
  3. Oct 12, 2023S-8 POS EDGAR
  4. Oct 12, 2023S-8 POS EDGAR
  5. Oct 12, 2023S-8 POS EDGAR
  6. Oct 12, 2023S-8 POS EDGAR
  7. Oct 12, 20238-K EDGAR
  8. Oct 10, 20238-K EDGAR
  9. Oct 10, 2023SC 13G EDGAR
  10. Oct 6, 20238-K EDGAR
  11. Sep 25, 2023SC 13G EDGAR
  12. Sep 25, 20238-K EDGAR
  13. Sep 19, 20234 EDGAR
  14. Sep 15, 2023DEFM14A EDGAR
  15. Sep 15, 20238-K EDGAR
  16. Sep 6, 20234 EDGAR
  17. Sep 6, 20233 EDGAR
  18. Sep 6, 20238-K EDGAR
  19. Aug 25, 20238-K EDGAR
  20. Aug 9, 202310-Q EDGAR

The 136 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 11 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 18, 2023Cormorant Asset Management, LP10% ownerBuy751,233$9.24$6.9MForm 4
Sep 15, 2023Cormorant Asset Management, LP10% ownerBuy1,401,505$9.05$12.7MForm 4
Apr 20, 2023Chen Bihua10% ownerBuy886,634$11.60$10.3MForm 4
Apr 19, 2023Chen Bihua10% ownerBuy951,909$11.15$10.6MForm 4
Apr 18, 2023Chen Bihua10% ownerBuy3,376,646$11.27$38.1MForm 4
Apr 17, 2023Cormorant Private Healthcare Fund III LP10% ownerBuy562,121$10.67$6.0MForm 4
Apr 14, 2023Cormorant Private Healthcare Fund III LP10% ownerBuy841,967$9.96$8.4MForm 4
Apr 13, 2023Cormorant Private Healthcare Fund III LP10% ownerBuy1,193,808$9.16$10.9MForm 4
Mar 16, 2023Cormorant Private Healthcare Fund III LP10% ownerBuy500,000$10.15$5.1MForm 4
Mar 15, 2023Cormorant Private Healthcare Fund III LP10% ownerBuy250,000$10.60$2.6MForm 4
Mar 14, 2023Cormorant Private Healthcare Fund III LP10% ownerBuy250,000$9.95$2.5MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Ambrx Biopharma Cayman, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAmbrx Biopharma Cayman, Inc.1
  • CIK0001836056
  • Employer ID (EIN)57-11473461
  • Filer status<br>emerging growth company1
  • Incorporated inCayman Islands1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address10975 North Torrey Pines Road, La Jolla, CA 920371
  • Phone(858) 875-24001
  • Shares outstanding434,070,056 as of Aug 7, 20235
  • Public float$75.9M as of Jun 30, 20223
  • On EDGAR sinceFeb 3, 20211
  • Filings164 in all: 4 (24), 8-K (21), 6-K (20), 3 (16), SC 13G/A (13), SC 13G (12), CORRESP (6), UPLOAD (5)1
    All 40 form types

    EFFECT (4), S-8 (4), S-8 POS (4), 10-Q (2), 25-NSE (2), 424B5 (2), CERT (2), SC 13D/A (2), SEC STAFF LETTER (2), 10-K (1), 15-12G (1), 20-F (1), 25 (1), 424B4 (1), 8-A12B (1), 8-A12B/A (1), ARS (1), DEF 14A (1), DEFA14A (1), DEFM14A (1), DEL AM (1), DRS (1), DRS/A (1), DRSLTR (1), F-1 (1), F-1/A (1), F-3 (1), F-6 (1), F-6/A (1), PRE 14A (1), S-3 (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2023
    Quarterly report (10-Q) Aug 9, 2023
    Proxy statement (DEF 14A) Apr 28, 2023
    Latest 8-K (8-K) Oct 12, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
    SEC EDGAROther events
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43